23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › CRISPR THERAPEUTICS AG › 2025-2026

CRISPR THERAPEUTICS AG 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CRISPR THERAPEUTICS AG’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 33Reported items
  • 513Asset managers, any item
  • 6,597Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 25 items on CRISPR THERAPEUTICS AG’s Form 8-K, filed June 4, 2026: 15 elected · 8 approved · 2 passed (calculated).

Dissent

Significant dissent: 2 directors (27.1%, 27.1% against); 1 say-on-pay vote (69.4% support).

Notable dissent: 1 other board item (40.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRISPR THERAPEUTICS AG in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by CRISPR THERAPEUTICS AG

These tallies are CRISPR THERAPEUTICS AG’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRISPR THERAPEUTICS AG — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2025 70,716,663288,652248,393 --0 99.6%Approved—
2. Approval of the Appropriation of Financial Results 70,554,606415,599283,503 --0 99.4%Approved—
3. Discharge of the Members of the Company’s Board of Directors and Executive Committee 48,379,678262,761112,414 --22,498,855 99.5%Approved—
Elect Director: Samarth Kulkarni, Ph.D. 47,043,9871,628,22682,640 --22,498,855 97%Elected—
Elect Director: Ali Behbahani, M.D. 35,498,39213,174,52381,938 --22,498,855 73%Elected—
Elect Director: Maria Fardis, Ph.D. 47,804,457874,20776,189 --22,498,855 98%Elected—
Elect Director: H. Edward Fleming Jr., M.D. 46,977,6361,686,12791,090 --22,498,855 97%Elected—
Elect Director: Simeon J. George, M.D. 47,435,7481,225,51993,586 --22,498,855 97%Elected—
Elect Director: John T. Greene 46,876,3671,793,10985,377 --22,498,855 96%Elected—
Elect Director: Katherine A. High, M.D. 47,779,619899,78775,447 --22,498,855 98%Elected—
Elect Director: Sandesh Mahatme, LL.M. 46,268,9642,405,58080,309 --22,498,855 95%Elected—
Elect Director: Briggs W. Morrison, M.D. 46,013,9112,659,68181,261 --22,498,855 95%Elected—
Elect Director: Christian Rommel, Ph.D. 47,802,202872,05080,601 --22,498,855 98%Elected—
Elect Director: Douglas A. Treco, Ph.D. 44,359,4534,317,38478,016 --22,498,855 91%Elected—
Elect Director: Ali Behbahani, M.D. 35,458,90813,198,64197,304 --22,498,855 73%Elected—
Elect Director: H. Edward Fleming Jr., M.D. 46,322,4762,341,51390,864 --22,498,855 95%Elected—
Elect Director: John T. Greene 46,319,6462,326,146109,061 --22,498,855 95%Elected—
Elect Director: Briggs W. Morrison, M.D. 45,317,6353,329,265107,953 --22,498,855 93%Elected—
7. Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law Requirements 33,742,00114,867,591145,261 --22,498,855 69%Approved—
8. Approval of an Increase to the Company’s Capital Band 69,408,9991,361,697483,012 --0 98%Approved—
9. Approval of an Increase to the Conditional Share Capital for the Conversion of Bonds and Similar Debt Instruments 47,341,0351,298,782115,036 --22,498,855 97%Approved—
10. Approval of the 2026 Plan 42,839,1995,763,564152,090 --22,498,855 88%Approved—
11. Re-election of the Independent Voting Rights Representative 70,290,203640,943322,562 --0 99.1%Passed (calculated)—
12. Re-election of the Auditors 69,875,653462,910915,145 --0 99.3%Passed (calculated)—
13. Transact Any Other Business that may Properly Come Before the 2026 Annual General Meeting or any Adjournment or Postponement thereof 29,000,33719,464,339290,177 --22,498,855 60%Approved—

Source: CRISPR THERAPEUTICS AG, Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the CRISPR THERAPEUTICS AG 2025-2026 meeting

513 asset managers disclosed a vote on at least one CRISPR THERAPEUTICS AG item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRISPR THERAPEUTICS AG’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Binding vote on maximum equity for members of the board of directors from the 2026 annual general meeting to the 2027…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

89% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 103 asset managers

Description as filed by funds: BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE BOARD OF DIRECTORS FROM THE 2026 ANNUAL GENERAL MEETING TO THE 2027 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 52 asset managers voting on “BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE BOARD OF DIRECTORS FROM THE 2026 ANNUAL GENERAL MEETING TO T” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
Charles Schwab0557,037 00Against
Vanguard286,3721,394 00For
State Street0198,049 00Against
Fidelity177,7430 00For
Equitable13,278122,735 00Mixed
Lincoln Financial6,490128,668 00Against
AMERICAN BEACON FUNDS125,1880 00For
American Century059,438 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against
SEI014,652 00Against
ProShares013,143 00Against
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments011,658 00Against
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Venerable Variable Insurance Trust08,432 00Against

Fund voting reports, all 52 managers: 7,321,136 for, 1,305,188 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 51 asset managers voting on “BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE BOARD OF DIRECTORS FROM THE 2026 ANNUAL GENERAL MEETING TO T” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
NEA Management Company, LLC1,060,0020 00For
Versant Venture Management, LLC148,8310 00For
Janney Montgomery Scott LLC024,211 00Against
Ipswich Investment Management Co., Inc.15,6730 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC04,945 00Against
HOLDERNESS INVESTMENTS CO2,4690 00For
SevenBridge Financial Group, LLC2,1500 00For
Vident Advisory, LLC2,1200 00For
Atlantic Union Bankshares Corp1,5660 00For
Waverly Advisors, LLC1,5320 00For
Bogart Wealth, LLC1,2500 00For
Sound View Wealth Advisors Group, LLC1,2140 00For
Formidable Asset Management, LLC1,1900 00For
ZACKS INVESTMENT MANAGEMENT8620 00For
DDD Partners, LLC8190 00For
WIMMER ASSOCIATES 1, LLC6500 00For
MERIDIAN INVESTMENT COUNSEL INC.5750 00For
Journey Advisory Group, LLC5000 00For
Naviter Wealth, LLC3500 00For
CARY STREET PARTNERS FINANCIAL LLC3400 00For
Summit Trail Advisors, LLC0338 00Against
Legacy Capital Wealth Partners, LLC3000 00For
Performance Wealth Partners, LLC3000 00For
Rodgers Brothers Inc.0300 00Against

Institutional-manager reports, all 51 managers: 3,283,860 for, 30,193 against. Showing the 25 largest; every one is in the interactive database (link above).

RE-ELECTION OF THE MEMBERS OF THE COMPENSATION COMMITTEE: BRIGGS W. MORRISON, M.D.

No official matchSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

94% of fund votes cast · no official result

FOR
Details: votes by 77 asset managers

The 77 asset managers below reported 11,106,682 for, 664,822 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 11,106,682AGAINST: 664,822
Largest asset managers voting on “RE-ELECTION OF THE MEMBERS OF THE COMPENSATION COMMITTEE: BRIGGS W. MORRISON, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
BlackRock908,1440 00For
Charles Schwab0557,037 00Against
ARK Venture Fund171,9260 00For
Natixis076,100 00Against
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
Investment Managers Series Trust II31,0000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan016,747 00Against
Ipswich Investment Management Co., Inc.15,6730 00For
SEI14,6520 00For
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
Venerable Variable Insurance Trust6,7570 00For
Lincoln Financial06,490 00Against
Loomis Sayles05,310 00Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC4,9450 00For
QUANTITATIVE MASTER SERIES LLC3,8000 00For
EA Series Trust3,5620 00For
Vanguard3,2823 00For
HOLDERNESS INVESTMENTS CO2,4690 00For
SevenBridge Financial Group, LLC2,1500 00For
Allianz02,134 00Against

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Discharge of the Members of the Company’s Board of Directors and Executive Committee

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 48,379,678AGAINST: 262,761
Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Discharge of the members of the Board of Directors and the Executive Committee.

CRISPR THERAPEUTICS AG’s own tally for this item (“3. Discharge of the Members of the Company’s Board of Directors and Executive Committee”): 48,379,678 for, 262,761 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Discharge of the Members of the Company’s Board of Directors and Executive Committee The discharge of the members of the Company’s Board of Directors and the Executive Committee from personal liability for their activities during the year ended December 31, 2025 was approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 19,691,680 for.

FOR
FOR: 19,691,680
Largest asset managers voting on “Discharge of the members of the Board of Directors and the Executive Committee.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial135,1580 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).

Re-election of the Independent Voting Rights Representative

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 70,290,203AGAINST: 640,943
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of the independent voting rights representative.

CRISPR THERAPEUTICS AG’s own tally for this item (“11. Re-election of the Independent Voting Rights Representative”): 70,290,203 for, 640,943 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,676,391 for.

FOR
FOR: 19,676,391
Largest asset managers voting on “Re-election of the independent voting rights representative.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial135,1580 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Samarth Kulkarni, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 47,043,987AGAINST: 1,628,226

Prior year: 98.1% for (June 5, 2025 meeting) ▼ 1.4 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D., as member and Chairman

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Samarth Kulkarni, Ph.D.”): 47,043,987 for, 1,628,226 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,375,839 for, 300,552 against.

FOR
FOR: 19,375,839AGAINST: 300,552
Largest asset managers voting on “Re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D.,” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard286,3761,390 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable13,278122,735 00Mixed
Lincoln Financial78,12157,037 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Maria Fardis, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 47,804,457AGAINST: 874,207

Prior year: 97.8% for (June 5, 2025 meeting) ▲ 0.4 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of Maria Fardis, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Maria Fardis, Ph.D.”): 47,804,457 for, 874,207 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,477,753 for, 198,637 against.

FOR
FOR: 19,477,753AGAINST: 198,637
Largest asset managers voting on “Re-election of Maria Fardis, Ph.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard286,7081,057 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable77,36858,645 00Mixed
Lincoln Financial80,24854,910 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Simeon J. George, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 47,435,748AGAINST: 1,225,519

Prior year: 97.8% for (June 5, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of Simeon J. George, M.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Simeon J. George, M.D.”): 47,435,748 for, 1,225,519 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,455,129 for, 221,262 against.

FOR
FOR: 19,455,129AGAINST: 221,262
Largest asset managers voting on “Re-election of Simeon J. George, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7651 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable77,36858,645 00Mixed
Lincoln Financial73,75861,400 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan016,747 00Against
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Katherine A. High, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 47,779,619AGAINST: 899,787

Prior year: 97.7% for (June 5, 2025 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of Katherine A. High, M.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Katherine A. High, M.D.”): 47,779,619 for, 899,787 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,471,893 for, 204,498 against.

FOR
FOR: 19,471,893AGAINST: 204,498
Largest asset managers voting on “Re-election of Katherine A. High, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable77,36858,645 00Mixed
Lincoln Financial80,24854,910 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Sandesh Mahatme, LL.M.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 46,268,964AGAINST: 2,405,580

Prior year: 97.8% for (June 5, 2025 meeting) ▼ 2.7 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of Sandesh Mahatme, LL.M.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Sandesh Mahatme, LL.M.”): 46,268,964 for, 2,405,580 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 18,847,258 for, 829,133 against.

FOR
FOR: 18,847,258AGAINST: 829,133
Largest asset managers voting on “Re-election of Sandesh Mahatme, LL.M.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab0557,037 00Against
Vanguard286,3761,390 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable77,36858,645 00Mixed
Lincoln Financial80,24854,910 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Christian Rommel, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 47,802,202AGAINST: 872,050

Prior year: 97.8% for (June 5, 2025 meeting) ▲ 0.4 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of Christian Rommel, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Christian Rommel, Ph.D.”): 47,802,202 for, 872,050 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,479,368 for, 197,023 against.

FOR
FOR: 19,479,368AGAINST: 197,023
Largest asset managers voting on “Re-election of Christian Rommel, Ph.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable77,36858,645 00Mixed
Lincoln Financial80,24854,910 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Douglas A. Treco, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 44,359,453AGAINST: 4,317,384

Prior year: 95.4% for (June 5, 2025 meeting) ▼ 4.2 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of Douglas A. Treco, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Douglas A. Treco, Ph.D.”): 44,359,453 for, 4,317,384 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Chris…”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 18,252,000 for, 1,424,390 against.

FOR
FOR: 18,252,000AGAINST: 1,424,390
Largest asset managers voting on “Re-election of Douglas A. Treco, Ph.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock46,415861,729 00Mixed
Charles Schwab557,0370 00For
Vanguard286,7061,059 00For
State Street0198,049 00Against
Fidelity138,92938,814 00Mixed
ARK Venture Fund171,9260 00For
Equitable64,09071,923 00Mixed
Lincoln Financial21,348113,810 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust040,875 00Against
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2026…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 68 asset managers

Description as filed by funds: Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 17 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Charles Schwab557,0370 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
JPMorgan16,7470 00For
SEI14,6520 00For
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
Venerable Variable Insurance Trust6,7570 00For
Lincoln Financial6,4900 00For
Vanguard3,2850 00For
Nationwide1,9900 00For
New York Life1,1730 00For
Brighthouse1,0010 00For
Prudential/PGIM4000 00For
Meeder Funds1440 00For
NYLIM VP FUNDS TRUST70 00For

Fund voting reports, all 17 managers: 705,516 for.

Institutional-manager reports: 51 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
NEA Management Company, LLC1,060,0020 00For
Versant Venture Management, LLC148,8310 00For
Janney Montgomery Scott LLC24,2110 00For
Ipswich Investment Management Co., Inc.15,6730 00For
Jasper Ridge Partners, L.P.9,5390 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC4,9450 00For
HOLDERNESS INVESTMENTS CO2,4690 00For
SevenBridge Financial Group, LLC2,1500 00For
Atlantic Union Bankshares Corp1,5660 00For
Waverly Advisors, LLC1,5320 00For
Bogart Wealth, LLC1,2500 00For
Sound View Wealth Advisors Group, LLC1,2140 00For
Formidable Asset Management, LLC1,1900 00For
ZACKS INVESTMENT MANAGEMENT8620 00For
DDD Partners, LLC8190 00For
WIMMER ASSOCIATES 1, LLC6500 00For
MERIDIAN INVESTMENT COUNSEL INC.5750 00For
Journey Advisory Group, LLC5000 00For
BIRCHBROOK, INC.4550 00For
Naviter Wealth, LLC3500 00For
CARY STREET PARTNERS FINANCIAL LLC3400 00For
Summit Trail Advisors, LLC3380 00For
Legacy Capital Wealth Partners, LLC3000 00For
Performance Wealth Partners, LLC3000 00For

Institutional-manager reports, all 51 managers: 3,321,627 for. Showing the 25 largest; every one is in the interactive database (link above).

Re-election of H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

90% of fund votes cast · no official result

FOR
Details: votes by 57 asset managers

The 57 asset managers below reported 8,290,485 for, 904,174 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,290,485AGAINST: 904,174
Largest asset managers voting on “Re-election of H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
Charles Schwab557,037557,037 00Mixed
Vanguard286,7061,059 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
Equitable13,278122,735 00Mixed
Lincoln Financial71,63163,527 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century59,4380 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
JPMorgan016,747 00Against
ETFis Series Trust I16,0460 00For
SEI14,6520 00For
ProShares13,1430 00For
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
AIG/SunAmerica10,9730 00For
Jasper Ridge Partners, L.P.9,5390 00For
Direxion Shares ETF Trust9,3960 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Re-election of Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

67% of fund votes cast · no official result

FORAGAINST
Details: votes by 56 asset managers

The 56 asset managers below reported 5,806,524 for, 2,821,560 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 5,806,524AGAINST: 2,821,560
Largest asset managers voting on “Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price2461,225,262 00Against
Charles Schwab0557,037 00Against
Vanguard1,890285,876 00Against
State Street198,0490 00For
Fidelity0177,743 00Against
Equitable0136,013 00Against
Lincoln Financial58,90076,258 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century059,438 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual033,247 00Against
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
JPMorgan016,747 00Against
ETFis Series Trust I016,046 00Against
SEI014,652 00Against
ProShares013,143 00Against
TARGET PORTFOLIO TRUST012,900 00Against
Russell Investments011,658 00Against
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Venerable Variable Insurance Trust08,432 00Against

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Re-election of John T. Greene

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

90% of fund votes cast · no official result

FOR
Details: votes by 56 asset managers

The 56 asset managers below reported 8,282,304 for, 904,206 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,282,304AGAINST: 904,206
Largest asset managers voting on “Re-election of John T. Greene” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
Charles Schwab557,037557,037 00Mixed
Vanguard287,7641,391 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
Equitable13,278122,735 00Mixed
Lincoln Financial71,63163,527 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century59,4380 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
JPMorgan016,747 00Against
ETFis Series Trust I16,0460 00For
SEI14,6520 00For
ProShares13,1430 00For
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
AIG/SunAmerica10,9730 00For
Direxion Shares ETF Trust9,3960 00For
Venerable Variable Insurance Trust8,4320 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Re-election of Briggs W. Morrison, M.D.

No official matchDIRECTOR ELECTIONS

93% of fund votes cast · no official result

FOR
Details: votes by 55 asset managers

The 55 asset managers below reported 8,022,929 for, 605,085 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,022,929AGAINST: 605,085
Largest asset managers voting on “Re-election of Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
Charles Schwab557,0370 00For
Vanguard287,7642 00For
State Street0198,049 00Against
Fidelity38,814138,929 00Mixed
Equitable13,278122,735 00Mixed
Lincoln Financial12,731122,427 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century59,4380 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
JPMorgan016,747 00Against
ETFis Series Trust I16,0460 00For
SEI14,6520 00For
ProShares13,1430 00For
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
AIG/SunAmerica10,9730 00For
Direxion Shares ETF Trust9,3960 00For
Venerable Variable Insurance Trust8,4320 00For

Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).

Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

73% of fund votes cast · no official result

FORAGAINST
Details: votes by 41 asset managers

The 41 asset managers below reported 5,771,944 for, 2,148,864 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 5,771,944AGAINST: 2,148,864
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price2461,225,262 00Against
Vanguard0284,481 00Against
State Street198,0490 00For
Fidelity0177,743 00Against
Equitable0136,013 00Against
Lincoln Financial58,90069,768 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century059,438 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual033,247 00Against
Guggenheim032,826 00Against
ETFis Series Trust I016,046 00Against
ProShares013,143 00Against
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Calvert07,475 00Against
Franklin Templeton06,651 00Against
Voya05,728 00Against
Allspring03,864 00Against
Morgan Stanley03,509 00Against
Blackstone Alternative Investment Funds03,400 00Against
Nationwide02,575 00Against
PENN SERIES FUNDS INC2,3320 00For
TIAA01,795 00Against

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Re-election of the members of the Compensation Committee: Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

86% of fund votes cast · no official result

FORAGAINST
Details: votes by 35 asset managers

The 35 asset managers below reported 10,041,772 for, 1,691,297 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 10,041,772AGAINST: 1,691,297
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
BlackRock0908,144 00Against
Charles Schwab0557,037 00Against
ARK Venture Fund171,9260 00For
Natixis076,100 00Against
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust040,875 00Against
Investment Managers Series Trust II31,0000 00For
Global X017,975 00Against
John Hancock017,087 00Against
JPMorgan016,747 00Against
SEI014,652 00Against
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments011,658 00Against
Venerable Variable Insurance Trust06,757 00Against
Lincoln Financial06,490 00Against
Loomis Sayles05,310 00Against
QUANTITATIVE MASTER SERIES LLC03,800 00Against
EA Series Trust3,5620 00For
Vanguard1,8901,395 00Mixed
Allianz02,134 00Against
Nationwide01,990 00Against
Formidable Asset Management, LLC1,1900 00For
New York Life01,173 00Against
Brighthouse01,001 00Against

Showing the 25 largest of 35 asset managers. All 35 are in the interactive database (link above).

Re-election of the members of the Compensation Committee - H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

99.0% of fund votes cast · no official result

FOR
Details: votes by 25 asset managers

The 25 asset managers below reported 10,996,916 for, 109,398 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 10,996,916AGAINST: 109,398
Largest asset managers voting on “Re-election of the members of the Compensation Committee - H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
BlackRock908,1440 00For
ARK Venture Fund171,9260 00For
Natixis076,100 00Against
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
Investment Managers Series Trust II31,0000 00For
John Hancock17,0870 00For
JPMorgan016,747 00Against
Lincoln Financial06,490 00Against
Loomis Sayles05,310 00Against
QUANTITATIVE MASTER SERIES LLC3,8000 00For
EA Series Trust3,5620 00For
Allianz02,134 00Against
Formidable Asset Management, LLC1,1900 00For
Vanguard201,059 00Against
Brighthouse01,001 00Against
REYNOLDS FUNDS INC7000 00For
Jackson National5110 00For
Crewe Advisors LLC3500 00For
Legacy Capital Wealth Partners, LLC0300 00Against
Amplify ETF Trust0257 00Against
Roberts Wealth Advisors, LLC2000 00For
WILSHIRE MUTUAL FUNDS INC1970 00For
Jacob Funds Inc.410 00For

Re-election of the members of the Compensation Committee - John T. Greene

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

99.0% of fund votes cast · no official result

FOR
Details: votes by 25 asset managers

The 25 asset managers below reported 10,998,530 for, 107,784 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 10,998,530AGAINST: 107,784
Largest asset managers voting on “Re-election of the members of the Compensation Committee - John T. Greene” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
BlackRock908,1440 00For
ARK Venture Fund171,9260 00For
Natixis076,100 00Against
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
Investment Managers Series Trust II31,0000 00For
John Hancock17,0870 00For
JPMorgan016,747 00Against
Lincoln Financial06,490 00Against
Loomis Sayles05,310 00Against
QUANTITATIVE MASTER SERIES LLC3,8000 00For
EA Series Trust3,5620 00For
Allianz02,134 00Against
Formidable Asset Management, LLC1,1900 00For
Vanguard1,0772 00For
Brighthouse01,001 00Against
REYNOLDS FUNDS INC7000 00For
Jackson National5110 00For
Crewe Advisors LLC3500 00For
Legacy Capital Wealth Partners, LLC3000 00For
Amplify ETF Trust2570 00For
Roberts Wealth Advisors, LLC2000 00For
WILSHIRE MUTUAL FUNDS INC1970 00For
Jacob Funds Inc.410 00For

Approval of an Increase to the Conditional Share Capital for the Conversion of Bonds and Similar Debt Instruments

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 47,341,035AGAINST: 1,298,782
Details: description as filed, official tally, votes by 74 asset managers

Description as filed by funds: Approval of an increase to the conditional share capital for the conversion of bonds and similar debt instruments.

CRISPR THERAPEUTICS AG’s own tally for this item (“9. Approval of an Increase to the Conditional Share Capital for the Conversion of Bonds and Similar Debt Instruments”): 47,341,035 for, 1,298,782 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 9 – Approval of an Increase to the Conditional Share Capital for the Conversion of Bonds and Similar Debt Instruments An increase to the conditional share capital for the conversion of bonds and similar debt instruments was approved with at least two thirds of the votes represented and the…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 74 asset managers below reported 19,424,085 for, 259,306 against.

FOR
FOR: 19,424,085AGAINST: 259,306
Largest asset managers voting on “Approval of an increase to the conditional share capital for the conversion of bonds and similar debt instrume” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7651 00For
State Street0198,049 00Against
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial76,25858,900 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 74 asset managers. All 74 are in the interactive database (link above).

Approval of an Increase to the Company’s Capital Band

Official resultOTHERReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 69,408,999AGAINST: 1,361,697
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Approval of an increase to the Company's capital band.

CRISPR THERAPEUTICS AG’s own tally for this item (“8. Approval of an Increase to the Company’s Capital Band”): 69,408,999 for, 1,361,697 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 8 – Approval of an Increase to the Company’s Capital Band An increase to the Company’s capital band was approved with at least two thirds of the votes represented and the absolute majority of the par value of the represented shares.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,672,829 for, 3,562 against.

FOR
FOR: 19,672,829AGAINST: 3,562
Largest asset managers voting on “Approval of an increase to the Company's capital band.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial135,1580 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 70,716,663AGAINST: 288,652
Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2025.

CRISPR THERAPEUTICS AG’s own tally for this item (“1. Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2025”): 70,716,663 for, 288,652 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 1 – Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2025 The Swiss management report, the consolidated financial statements and the statutory financial statements of the Com…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 19,683,416 for.

FOR
FOR: 19,683,416
Largest asset managers voting on “Approval of the Swiss management report, the consolidated financial statements and the statutory financial sta” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial135,1580 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).

Approval of the Appropriation of Financial Results

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 70,554,606AGAINST: 415,599
Details: description as filed, official tally, votes by 74 asset managers

Description as filed by funds: Approval of the appropriation of financial results.

CRISPR THERAPEUTICS AG’s own tally for this item (“2. Approval of the Appropriation of Financial Results”): 70,554,606 for, 415,599 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Approval of the Appropriation of Financial Results The proposal to carry forward the net loss resulting from the appropriation of financial results was approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 74 asset managers below reported 19,676,416 for.

FOR
FOR: 19,676,416
Largest asset managers voting on “Approval of the appropriation of financial results.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial135,1580 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 74 asset managers. All 74 are in the interactive database (link above).

Transact Any Other Business that may Properly Come Before the 2026 Annual General Meeting or any Adjournment or…

Official resultOTHERReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

60% Approved · of votes cast

FOR 60%AGAINST
FOR: 29,000,337AGAINST: 19,464,339
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Transact any other business that may properly come before the 2026 Annual General Meeting or any adjournment or postponement thereof.

CRISPR THERAPEUTICS AG’s own tally for this item (“13. Transact Any Other Business that may Properly Come Before the 2026 Annual General Meeting or any Adjournment or Postponement thereof”): 29,000,337 for, 19,464,339 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 13 – Transact Any Other Business that may Properly Come Before the 2026 Annual General Meeting or any Adjournment or Postponement thereof The proposal for the transaction of any other business that properly came before the Annual Meeting or any adjournment or postponement thereof, to follo…”
Support: 60% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 15,559,697 for, 4,116,693 against.

FORAGAINST
FOR: 15,559,697AGAINST: 4,116,693
Largest asset managers voting on “Transact any other business that may properly come before the 2026 Annual General Meeting or any adjournment o” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price01,225,508 00Against
BlackRock0908,144 00Against
Charles Schwab0557,037 00Against
Vanguard829286,936 00Against
State Street0198,049 00Against
Fidelity0177,743 00Against
ARK Venture Fund171,9260 00For
Equitable0136,013 00Against
Lincoln Financial6,490128,668 00Against
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century059,438 00Against
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust040,875 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual033,247 00Against
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
John Hancock017,087 00Against
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Binding vote on maximum variable compensation for members of the executive committee for the current year ending…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 103 asset managers

Description as filed by funds: BINDING VOTE ON MAXIMUM VARIABLE COMPENSATION FOR MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE CURRENT YEAR ENDING DECEMBER 31, 2026.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 52 asset managers voting on “BINDING VOTE ON MAXIMUM VARIABLE COMPENSATION FOR MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE CURRENT YEAR ENDI” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,262246 00For
Charles Schwab557,0370 00For
Vanguard287,7624 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
Equitable71,92364,090 00Mixed
Lincoln Financial120,30014,858 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century059,438 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against
SEI14,6520 00For
ProShares013,143 00Against
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Venerable Variable Insurance Trust6,7571,675 00Mixed

Fund voting reports, all 52 managers: 8,197,690 for, 428,634 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 50 asset managers voting on “BINDING VOTE ON MAXIMUM VARIABLE COMPENSATION FOR MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE CURRENT YEAR ENDI” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
NEA Management Company, LLC1,060,0020 00For
Versant Venture Management, LLC148,8310 00For
Janney Montgomery Scott LLC24,2110 00For
Jasper Ridge Partners, L.P.9,5390 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC4,9450 00For
HOLDERNESS INVESTMENTS CO2,4690 00For
SevenBridge Financial Group, LLC2,1500 00For
Vident Advisory, LLC2,1200 00For
Atlantic Union Bankshares Corp1,5660 00For
Waverly Advisors, LLC1,5320 00For
Bogart Wealth, LLC1,2500 00For
Sound View Wealth Advisors Group, LLC1,2140 00For
Formidable Asset Management, LLC1,1900 00For
ZACKS INVESTMENT MANAGEMENT8620 00For
DDD Partners, LLC8190 00For
WIMMER ASSOCIATES 1, LLC6500 00For
MERIDIAN INVESTMENT COUNSEL INC.5750 00For
Journey Advisory Group, LLC5000 00For
BIRCHBROOK, INC.4550 00For
Naviter Wealth, LLC3500 00For
CARY STREET PARTNERS FINANCIAL LLC3400 00For
Summit Trail Advisors, LLC3380 00For
Legacy Capital Wealth Partners, LLC3000 00For
Performance Wealth Partners, LLC3000 00For

Institutional-manager reports, all 50 managers: 3,307,943 for, 10 against. Showing the 25 largest; every one is in the interactive database (link above).

Approval of the 2026 Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

88% Approved · of votes cast

FOR 88%
FOR: 42,839,199AGAINST: 5,763,564
Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.

CRISPR THERAPEUTICS AG’s own tally for this item (“10. Approval of the 2026 Plan”): 42,839,199 for, 5,763,564 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 10 – Approval of the 2026 Plan The 2026 Plan was approved.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 68 asset managers voting on “Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7633 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial120,30014,858 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century059,438 00Against
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
John Hancock13416,953 00Against
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against

Fund voting reports, all 68 managers: 19,418,451 for, 255,830 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 13 asset managers voting on “Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC1,060,0020 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC4,9450 00For
Vident Advisory, LLC2,1200 00For
Formidable Asset Management, LLC1,1900 00For
BIRCHBROOK, INC.4550 00For
Crewe Advisors LLC3500 00For
Legacy Capital Wealth Partners, LLC3000 00For
Roberts Wealth Advisors, LLC2000 00For
Royal Capital Wealth Management, LLC1310 00For
CHECK CAPITAL MANAGEMENT INC/CA1000 00For
MARCO INVESTMENT MANAGEMENT LLC700 00For
Socha Financial Group, LLC250 00For
Hendershot Investments Inc.010 00Against

Institutional-manager reports, all 13 managers: 1,069,888 for, 10 against.

Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 20 wordings of this item as funds reported it.

69% Approved · of votes cast

FOR 69%AGAINST
FOR: 33,742,001AGAINST: 14,867,591

Prior year: 71.2% for (June 5, 2025 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 506 asset managers

Description as filed by funds: NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS UNDER U.S. SECURITIES LAW REQUIREMENTS.

CRISPR THERAPEUTICS AG’s own tally for this item (“7. Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law Requirements”): 33,742,001 for, 14,867,591 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 7 – Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law Requirements The compensation paid to the named executive officers was approved on a non-binding basis.”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 70 asset managers voting on “NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS UNDER U.S. SECURI” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group05,387,072 00Against
T. Rowe Price1,225,262246 00For
BlackRock908,1440 00For
Charles Schwab0557,037 00Against
Vanguard286,3721,394 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
ARK Venture Fund171,9260 00For
Equitable13,278122,735 00Mixed
Lincoln Financial65,39069,768 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
Natixis076,100 00Against
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
John Hancock13416,953 00Against
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against

Fund voting reports, all 70 managers: 13,062,643 for, 6,620,958 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 452 asset managers voting on “NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS UNDER U.S. SECURI” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group1506,029,384 00Against
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
T. Rowe Price1,811,725112,806 00Mixed
Amova Asset Management Co., Ltd.01,835,407 00Against
BlackRock1,217,1425,721 00For
NEA Management Company, LLC1,060,0020 00For
State Street850,2825,863 00For
Charles Schwab0557,219 00Against
ARK Investment Management LLC549,0000 00For
Loomis Sayles0544,763 00Against
Northern Trust0403,093 00Against
Green Alpha Advisors, LLC0271,425 00Against
Vestmark Advisory Solutions, Inc.0251,455 00Against
Fidelity0215,616 00Against
WELLS FARGO CLEARING SERVICES, LLC162,8560 00For
Versant Venture Management, LLC148,8310 00For
MELLON INVESTMENTS Corp146,5800 00For
RBC Capital Markets, LLC0140,405 00Against
Vanguard122,1251,399 00For
UBS0119,974 00Against
Reynders McVeigh Capital Management, LLC0106,533 00Against
AllianceBernstein094,286 00Against
STATE OF MICHIGAN RETIREMENT SYSTEM082,547 00Against
ROCKEFELLER FINANCIAL LLC71,5760 00For
Edward D. Jones & Co., L.P.061,462 00Against

Institutional-manager reports, all 452 managers: 8,735,474 for, 12,228,900 against, 25,390 abstained, 40,889 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Non-binding advisory vote on the 2025 compensation report.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

91% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 127 asset managers

Description as filed by funds: NON-BINDING ADVISORY VOTE ON THE 2025 COMPENSATION REPORT.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 52 asset managers voting on “NON-BINDING ADVISORY VOTE ON THE 2025 COMPENSATION REPORT.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,262246 00For
Charles Schwab0557,037 00Against
Vanguard286,3721,394 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
Equitable13,278122,735 00Mixed
Lincoln Financial65,39069,768 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century59,4380 00For
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against
SEI014,652 00Against
ProShares013,143 00Against
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments011,658 00Against
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Venerable Variable Insurance Trust08,432 00Against

Fund voting reports, all 52 managers: 7,506,432 for, 1,119,892 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 72 asset managers voting on “NON-BINDING ADVISORY VOTE ON THE 2025 COMPENSATION REPORT.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
NEA Management Company, LLC1,060,0020 00For
Versant Venture Management, LLC148,8310 00For
Ipswich Investment Management Co., Inc.15,6730 00For
Jasper Ridge Partners, L.P.9,5390 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC04,945 00Against
CWM, LLC4,4980 00For
HOLDERNESS INVESTMENTS CO2,4690 00For
Argent Trust Co02,361 00Against
SevenBridge Financial Group, LLC2,1500 00For
Wealth Alliance Advisory Group, LLC2,1440 00For
Vident Advisory, LLC2,1200 00For
Atlantic Union Bankshares Corp1,5660 00For
Waverly Advisors, LLC1,5320 00For
Bogart Wealth, LLC1,2500 00For
Bath Savings Trust Co1,2250 00For
Sound View Wealth Advisors Group, LLC1,2140 00For
Formidable Asset Management, LLC1,1900 00For
ZACKS INVESTMENT MANAGEMENT8620 00For
DDD Partners, LLC8190 00For
AMERICAN NATIONAL BANK & TRUST00 8000Abstain
WIMMER ASSOCIATES 1, LLC6500 00For
Pine Valley Investments Ltd Liability Co6000 00For
MERIDIAN INVESTMENT COUNSEL INC.5750 00For
Argent Advisors, Inc.0500 00Against

Institutional-manager reports, all 72 managers: 3,302,940 for, 9,569 against, 1,173 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2026…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 103 asset managers

Description as filed by funds: Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 52 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group5,387,0720 00For
T. Rowe Price1,225,262246 00For
Charles Schwab557,0370 00For
Vanguard287,7624 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
Equitable71,92364,090 00Mixed
Lincoln Financial120,30014,858 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century059,438 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust22,3000 00For
Global X17,9750 00For
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against
SEI14,6520 00For
ProShares013,143 00Against
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments11,6580 00For
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Venerable Variable Insurance Trust6,7571,675 00Mixed

Fund voting reports, all 52 managers: 8,197,690 for, 428,634 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 50 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
NEA Management Company, LLC1,060,0020 00For
Versant Venture Management, LLC148,8310 00For
Janney Montgomery Scott LLC24,2110 00For
Jasper Ridge Partners, L.P.9,5390 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC4,9450 00For
HOLDERNESS INVESTMENTS CO2,4690 00For
SevenBridge Financial Group, LLC2,1500 00For
Vident Advisory, LLC2,1200 00For
Atlantic Union Bankshares Corp1,5660 00For
Waverly Advisors, LLC1,5320 00For
Bogart Wealth, LLC1,2500 00For
Sound View Wealth Advisors Group, LLC1,2140 00For
Formidable Asset Management, LLC1,1900 00For
ZACKS INVESTMENT MANAGEMENT8620 00For
DDD Partners, LLC8190 00For
WIMMER ASSOCIATES 1, LLC6500 00For
MERIDIAN INVESTMENT COUNSEL INC.5750 00For
Journey Advisory Group, LLC5000 00For
BIRCHBROOK, INC.4550 00For
Naviter Wealth, LLC3500 00For
CARY STREET PARTNERS FINANCIAL LLC3400 00For
Summit Trail Advisors, LLC3380 00For
Legacy Capital Wealth Partners, LLC3000 00For
Performance Wealth Partners, LLC3000 00For

Institutional-manager reports, all 50 managers: 3,307,643 for, 310 against. Showing the 25 largest; every one is in the interactive database (link above).

Binding vote on maximum equity for members of the executive committee from the 2026 annual general meeting to the 2027…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

45% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 101 asset managers

Description as filed by funds: BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE EXECUTIVE COMMITTEE FROM THE 2026 ANNUAL GENERAL MEETING TO THE 2027 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 52 asset managers voting on “BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE EXECUTIVE COMMITTEE FROM THE 2026 ANNUAL GENERAL MEETING TO ” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group05,387,072 00Against
T. Rowe Price1,225,262246 00For
Charles Schwab0557,037 00Against
Vanguard286,3721,394 00For
State Street198,0490 00For
Fidelity38,814138,929 00Mixed
Equitable13,278122,735 00Mixed
Lincoln Financial65,39069,768 00Mixed
AMERICAN BEACON FUNDS125,1880 00For
American Century059,438 00Against
RMB INVESTORS TRUST037,600 00Against
Northwestern Mutual33,2470 00For
Guggenheim032,826 00Against
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust022,300 00Against
Global X017,975 00Against
JPMorgan16,7470 00For
ETFis Series Trust I016,046 00Against
SEI014,652 00Against
ProShares013,143 00Against
TARGET PORTFOLIO TRUST12,9000 00For
Russell Investments011,658 00Against
AIG/SunAmerica010,973 00Against
Direxion Shares ETF Trust09,396 00Against
Venerable Variable Insurance Trust08,432 00Against

Fund voting reports, all 52 managers: 2,059,922 for, 6,566,402 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 48 asset managers voting on “BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE EXECUTIVE COMMITTEE FROM THE 2026 ANNUAL GENERAL MEETING TO ” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP2,038,7630 00For
NEA Management Company, LLC1,060,0020 00For
Versant Venture Management, LLC148,8310 00For
Janney Montgomery Scott LLC024,211 00Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC04,945 00Against
HOLDERNESS INVESTMENTS CO2,4690 00For
SevenBridge Financial Group, LLC2,1500 00For
Vident Advisory, LLC2,1200 00For
Atlantic Union Bankshares Corp1,5660 00For
Waverly Advisors, LLC1,5320 00For
Bogart Wealth, LLC1,2500 00For
Sound View Wealth Advisors Group, LLC1,2140 00For
Formidable Asset Management, LLC1,1900 00For
ZACKS INVESTMENT MANAGEMENT8620 00For
DDD Partners, LLC8190 00For
WIMMER ASSOCIATES 1, LLC6500 00For
MERIDIAN INVESTMENT COUNSEL INC.5750 00For
Journey Advisory Group, LLC5000 00For
Naviter Wealth, LLC3500 00For
CARY STREET PARTNERS FINANCIAL LLC3400 00For
Summit Trail Advisors, LLC0338 00Against
Legacy Capital Wealth Partners, LLC3000 00For
Performance Wealth Partners, LLC3000 00For
Rodgers Brothers Inc.0300 00Against
Burns Matteson Capital Management, LLC2880 00For

Institutional-manager reports, all 48 managers: 3,267,824 for, 30,135 against. Showing the 25 largest; every one is in the interactive database (link above).

Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on…

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 59 asset managers

Description as filed by funds: Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report: Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

The 59 asset managers below reported 18,971,235 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 18,971,235
Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Vanguard284,4810 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial128,6680 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
John Hancock17,0870 00For
ETFis Series Trust I16,0460 00For
ProShares13,1430 00For
AIG/SunAmerica10,9730 00For
Direxion Shares ETF Trust9,3960 00For
Calvert7,4750 00For
Franklin Templeton6,6510 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Re-election of the Auditors

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 69,875,653AGAINST: 462,910
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: Re-election of the auditors.

CRISPR THERAPEUTICS AG’s own tally for this item (“12. Re-election of the Auditors”): 69,875,653 for, 462,910 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 19,654,021 for, 22,320 abstained.

FOR
FOR: 19,654,021ABSTAIN: 22,320
Largest asset managers voting on “Re-election of the auditors.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,776,0430 00For
Capital Group5,387,0720 00For
T. Rowe Price1,225,5080 00For
BlackRock908,1440 00For
Charles Schwab557,0370 00For
Vanguard287,7660 00For
State Street198,0490 00For
Fidelity177,7430 00For
ARK Venture Fund171,9260 00For
Equitable136,0130 00For
Lincoln Financial135,1580 00For
AMERICAN BEACON FUNDS125,1880 00For
Natixis76,1000 00For
American Century59,4380 00For
Clough Global Equity Fund41,2700 00For
Bridge Builder Trust40,8750 00For
RMB INVESTORS TRUST37,6000 00For
Northwestern Mutual33,2470 00For
Guggenheim32,8260 00For
Investment Managers Series Trust II31,0000 00For
Capitol Series Trust00 22,3000Abstain
Global X17,9750 00For
John Hancock17,0870 00For
JPMorgan16,7470 00For
ETFis Series Trust I16,0460 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of June 5, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest CRISPR THERAPEUTICS AG shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 96,385,506 shares outstanding at the time of that meeting.

Fund voting reports: top CRISPR THERAPEUTICS AG shareholders by shares voted on “NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2025-2026
#Asset manager % of shares outstanding
1ARK ETF Trust 10.14%
2Capital Group 5.59%
3T. Rowe Price 1.27%
4BlackRock 0.94%
5Charles Schwab 0.58%
6Vanguard 0.30%
7State Street 0.21%
8Fidelity 0.18%
9ARK Venture Fund 0.18%
10Equitable 0.14%
Institutional-manager reports: top CRISPR THERAPEUTICS AG shareholders by shares voted on “NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2025-2026
#Asset manager % of shares outstanding
1Capital Group 6.26%
2SR ONE CAPITAL MANAGEMENT, LP 2.12%
3T. Rowe Price 2.00%
4Amova Asset Management Co., Ltd. 1.90%
5BlackRock 1.27%
6NEA Management Company, LLC 1.10%
7State Street 0.89%
8Charles Schwab 0.58%
9ARK Investment Management LLC 0.57%
10Loomis Sayles 0.57%

Reported CRISPR THERAPEUTICS AG holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CRISPR THERAPEUTICS AG holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
ARK Investment Management LLC11,313,623 11.74%Schedule 13G, filed April 30, 2026
BlackRock7,680,073 7.97%Form 13F, quarter ended March 31, 2026
ORBIS INVESTMENT MANAGEMENT LTD5,433,344 5.64%Schedule 13G, filed August 14, 2026
Capital World Investors4,929,428 5.11%Schedule 13G, filed May 14, 2026
State Street3,982,500 4.13%Form 13F, quarter ended March 31, 2026
Geode Capital2,377,164 2.47%Form 13F, quarter ended March 31, 2026
Vanguard Group2,268,394 2.35%Form 13F, quarter ended March 31, 2026
Simeon J. George, M.D.2,188,680 2.27%Proxy statement (DEF 14A), table as of March 31, 2026
FMR (Fidelity)1,954,694 2.03%Form 13F, quarter ended March 31, 2026
Samarth Kulkarni, Ph.D.1,603,279 1.66%Proxy statement (DEF 14A), table as of March 31, 2026

Percentages above are of 96,385,506 shares outstanding, as reported by CRISPR THERAPEUTICS AG on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CRISPR THERAPEUTICS AG's shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 513 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 6,597 separate fund positions. Their filings are grouped here into 33 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS… — CRISPR THERAPEUTICS AG's filing reports the proposal as approved, with 69% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CRISPR THERAPEUTICS AG's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRISPR THERAPEUTICS AG’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CRISPR THERAPEUTICS AG proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “CRISPR THERAPEUTICS (CRSP) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crispr-therapeutics-ag/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.